License and supply agreement with Genuine Health
RNS & Investor News
Joint Development Agreement signed with Royal DSM
05 April 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic® technology platform.
Royal DSM is a global science based company active in health, nutrition and materials with approximately 25,000 employees and annual net sales in the region of €10 billion. Its Nutritional Products business is one of the world's leading suppliers of vitamins, carotenoids, nutritional lipids and other ingredients in the food, pharmaceutical and personal care industries.
If successful, the agreement allows both parties to agree commercial terms such that OptiBiotix grants an exclusive licence to DSM in the DSM field, and an option to license in other fields, in return for royalty payments on sales of future products.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a joint development agreement with DSM, one of the world's leading suppliers of nutritional ingredients. We believe that OptiBiotix's strong science base together with DSM's innovation focus and global reach will help both companies bring better science and better health to people around the world."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
|Tel: 020 7148 7900|
|Hybridan LLP (Joint Broker)
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd (Joint Broker)
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix Health Plc - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About Royal DSM www.dsm.com
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020